David Mayleben

2.1k total citations · 1 hit paper
30 papers, 1.3k citations indexed

About

David Mayleben is a scholar working on Cognitive Neuroscience, Experimental and Cognitive Psychology and Endocrine and Autonomic Systems. According to data from OpenAlex, David Mayleben has authored 30 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Cognitive Neuroscience, 23 papers in Experimental and Cognitive Psychology and 9 papers in Endocrine and Autonomic Systems. Recurrent topics in David Mayleben's work include Sleep and related disorders (23 papers), Sleep and Wakefulness Research (23 papers) and Circadian rhythm and melatonin (9 papers). David Mayleben is often cited by papers focused on Sleep and related disorders (23 papers), Sleep and Wakefulness Research (23 papers) and Circadian rhythm and melatonin (9 papers). David Mayleben collaborates with scholars based in United States, Switzerland and Germany. David Mayleben's co-authors include Gary Zammit, Thomas Roth, Martin B. Scharf, Russell Rosenberg, Dalma Seboek Kinter, Ingo Fietze, Scott Pain, Margaret Moline, Shobha Dhadda and Alan Lankford and has published in prestigious journals such as Annals of Neurology, The Lancet Neurology and The American Journal of Medicine.

In The Last Decade

David Mayleben

29 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials

2022 136 citations Emmanuel Mignot, David Mayleben et al. The Lancet Neurology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Mayleben United States	17	864	836	519	133	107	30	1.3k
Sharon Schutte-Rodin United States	10	919 1.1×	1.2k 1.4×	442 0.9×	324 2.4×	97 0.9×	22	1.6k
J.F. Pagel United States	17	455 0.5×	489 0.6×	169 0.3×	164 1.2×	53 0.5×	47	800
Lauren Broch United States	4	945 1.1×	1.3k 1.5×	429 0.8×	202 1.5×	30 0.3×	4	1.6k
Ling‐Ling Tsai Taiwan	15	364 0.4×	444 0.5×	160 0.3×	147 1.1×	144 1.3×	31	960
Jana R. Cooke United States	9	568 0.7×	577 0.7×	356 0.7×	436 3.3×	76 0.7×	9	1.0k
Mina Kobayashi Japan	16	330 0.4×	302 0.4×	240 0.5×	268 2.0×	81 0.8×	33	878
Bharati Prasad United States	19	398 0.5×	322 0.4×	509 1.0×	665 5.0×	286 2.7×	63	1.4k
Gwendolyn Niebler United States	10	483 0.6×	417 0.5×	217 0.4×	224 1.7×	24 0.2×	23	924
Deirdre A. Conroy United States	20	656 0.8×	836 1.0×	243 0.5×	109 0.8×	18 0.2×	53	1.2k
James K. Walsh United States	8	634 0.7×	796 1.0×	313 0.6×	81 0.6×	14 0.1×	11	961

Countries citing papers authored by David Mayleben

Since Specialization

Citations

This map shows the geographic impact of David Mayleben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Mayleben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Mayleben more than expected).

Fields of papers citing papers by David Mayleben

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Mayleben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Mayleben. The network helps show where David Mayleben may publish in the future.

Co-authorship network of co-authors of David Mayleben

This figure shows the co-authorship network connecting the top 25 collaborators of David Mayleben. A scholar is included among the top collaborators of David Mayleben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Mayleben. David Mayleben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fietze, Ingo, Claudio L. Bassetti, David Mayleben, et al.. (2022). Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial. Drugs & Aging. 39(10). 795–810. 34 indexed citations

Mignot, Emmanuel, David Mayleben, Ingo Fietze, et al.. (2022). Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. The Lancet Neurology. 21(2). 125–139. 136 indexed citations breakdown →

Moline, Margaret, Gary Zammit, Jocelyn Y. Cheng, et al.. (2021). Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder. Journal of Clinical Sleep Medicine. 17(6). 1167–1174. 31 indexed citations

Mayleben, David, Russell Rosenberg, Kate Pinner, Ziad Hussein, & Margaret Moline. (2021). Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study. SLEEP Advances. 2(1). 3 indexed citations

Dauvilliers, Yves, Gary Zammit, Ingo Fietze, et al.. (2020). Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder. Annals of Neurology. 87(3). 347–356. 103 indexed citations

Rosenberg, Russell, Patricia Murphy, Gary Zammit, et al.. (2019). Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder. JAMA Network Open. 2(12). e1918254–e1918254. 159 indexed citations

Moline, Margaret, Patricia Murphy, Kate Pinner, et al.. (2019). 0369 Effect of Lemborexant on Sleep Architecture in Older Adults with Insomnia Disorder. SLEEP. 42(Supplement_1). A150–A150. 3 indexed citations

Dauvilliers, Yves, Gary Zammit, Ingo Fietze, et al.. (2019). 0375 A Novel Dual Orexin Receptor Antagonist (ACT-541468) to Treat Insomnia: A Randomized, Double-Blind, Placebo-Controlled, Active-Reference Phase 2 Study. SLEEP. 42(Supplement_1). A152–A153. 1 indexed citations

Murphy, Patricia, Margaret Moline, David Mayleben, et al.. (2017). Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study. Journal of Clinical Sleep Medicine. 13(11). 1289–1299. 119 indexed citations

10.

Struyk, Arie, Cynthia Gargano, S. Aubrey Stoch, et al.. (2016). Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects. European Neuropsychopharmacology. 26(10). 1649–1656. 19 indexed citations

11.

Spiegelstein, Ofer, Jasper Stevens, Joop van Gerven, et al.. (2016). Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects. Journal of Psychopharmacology. 30(10). 983–993. 7 indexed citations

12.

Rosenberg, Russell, Steven Hull, D. Alan Lankford, et al.. (2014). A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter, Polysomnographic Study of Gabapentin in Transient Insomnia Induced by Sleep Phase Advance. Journal of Clinical Sleep Medicine. 10(10). 1093–1100. 22 indexed citations

13.

Roth, Thomas, Gary Zammit, Alan Lankford, et al.. (2010). Nonrestorative Sleep as a Distinct Component of Insomnia. SLEEP. 33(4). 449–458. 81 indexed citations

14.

Scharf, Martin B., Steven Hull, Martin A. Cohn, et al.. (2008). Efficacy and Safety of Doxepin 1 mg, 3 mg, and 6 mg in Elderly Patients With Primary Insomnia. The Journal of Clinical Psychiatry. 69(10). 1557–1564. 76 indexed citations

15.

Walsh, James K., David Mayleben, Christine J. Guico‐Pabia, et al.. (2007). Efficacy of the selective extrasynaptic GABAA agonist, gaboxadol, in a model of transient insomnia: A randomized, controlled clinical trial. Sleep Medicine. 9(4). 393–402. 19 indexed citations

16.

Roth, Thomas, David Mayleben, Bruce Corser, & Nikhilesh Singh. (2007). Daytime pharmacodynamic and pharmacokinetic evaluation of low‐dose sublingual transmucosal zolpidem hemitartrate. Human Psychopharmacology Clinical and Experimental. 23(1). 13–20. 20 indexed citations

17.

Coyle, Michael, et al.. (2006). Evaluation of an ambulatory system for the quantification of cough frequency in patients with chronic obstructive pulmonary disease. 1(4). 137–138. 9 indexed citations

18.

Coyle, Michael, D. Barry Keenan, Linda S. Henderson, et al.. (2005). Evaluation of an ambulatory system for the quantification of cough frequency in patients with chronic obstructive pulmonary disease. PubMed. 1(1). 3–3. 97 indexed citations

19.

Zemlan, Frank P., J.J. Mulchahey, Martin B. Scharf, et al.. (2005). The Efficacy and Safety of the Melatonin Agonist beta-Methyl-6-Chloromelatonin in Primary Insomnia. The Journal of Clinical Psychiatry. 66(3). 384–390. 52 indexed citations

20.

Scharf, Martin B. & David Mayleben. (1989). Comparative effects of prazosin and hydrochlorothiazide on sexual function in hypertensive men. The American Journal of Medicine. 86(1). 110–112. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact